Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Correia-Rodrigues A, Ribeiro-Rodrigues T, Goncalves L, Almeida JP, Ferreira MJ, Girao H
Research applications In-vitro modeling of synergistic GHRH/GHRP receptor cross-talk Pre-clinical study of pulsatile GH-secretagogue dynamics Comparative receptor-pathway research (cAMP vs calcium convergence) Reference standard for analytical characterization of blended preparations Key facts Combines a GHRH-receptor analog with a selective GHS-R1a agonist Nominal 5mg + 5mg per-component loading per vial Components act through mechanistically independent, convergent pathways Supplied as a co-lyophilized research powder for in-vitro use Product specifications Class: GHRH analog + GHRP/ghrelin-receptor agonist research blend Also known as: Mod-GRF + Ipamorelin blend Form: Lyophilized powder vial Purity: 99% (HPLC verified) Testing: Independent third-party HPLC + mass spectrometry Documentation: Certificate of analysis per batch Storage: Store lyophilized at -20C
Subcutaneous injection Subcutaneous injection remains the reference standard for peptide administration
However, a virus, such as SARS-CoV-2, combines with angiotensin-converting enzyme 2 (ACE2), subsequently binds to Toll-like receptors, and shows the same effect (Schulte et al., 2011)
US$ 28.12
US$ 20.07
US$ 21.09
